If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||
![]() Tissue AntigensVolume 67 Issue 1, Pages 1 - 9 Published Online: 14 Dec 2005 © 2010 John Wiley & Sons A/S The official journal of the European Federation for Immunogenetics
Abstract | References | Full Text: HTML, PDF (Size: 380K) | Related Articles | Citation Tracking REVIEW ARTICLE SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation Copyright Blackwell Munksgaard, 2006 KEYWORDS (4–9) SOCS1 • cytokines • inflammation • interferons • T cells • tumours Abstract
Suppressor of cytokine signalling-1 (SOCS1), as the name implies, is a protein that functions as a negative regulator of cytokine signalling. Initially characterized for its ability to inhibit JAK phosphorylation and function, SOCS1 also targets proteins for degradation by the proteosome machinery. The expression of SOCS1 can be regulated at the transcription, translation and protein level. Despite the broad spectrum of cytokines that can induce SOCS1 expression and/or be inhibited by SOCS1 in vitro, the use of genetically modified mice has revealed a more specific role for SOCS1 in vivo including a critical role in the regulation of IFNγ signalling. In addition, SOCS1 has a complex role in T cell activation, and studies have revealed significant roles for SOCS1 in the regulation of IL-4, IL-12 and IL-15 in vivo. Interestingly, SOCS1 action is not limited to the regulation of the classical JAK/STAT-signalling pathway, because SOCS1 also inhibits cytokines like insulin and toll-like receptor signal transduction, neither of which activates the JAK/STAT pathway. Evidence is emerging for a role for aberrant SOCS1 expression in human disease, particularly in a number of malignancies. Received 3 October 2005; revised 10 October 2005; accepted 11 October 2005 |